BioSpace News Archive

With concerns over the costs of prescription drugs taking center stage in American politics during a time when there are shortages of insulin and medical devices like EpiPens, it’s no wonder that the general public is frustrated and is calling on the government to take action of some kind.

Most people would prefer to take a pill over an injection, and even an injection over an infusion. But not all drugs can be taken orally. In particular, this applies to most biologics, including insulin.

Abpro, based in Woburn, Mass., inked a deal worth up to $4 billion with China-based Nanjing Chia Tai Tianqing Pharmaceutical Company, known as NJCTTQ, a global pharmaceutical company.

An analysis of the genetics of nearly 95,000 people across the United States and Europe who have been diagnosed with Alzheimer’s disease has led to the discovery of four new genetic variants in the body that can increase the risk of developing the form of dementia.

ImmunoGen’s FORWARD I trial was testing the safety and efficacy of mirvetuximab soravtansine compared to chemotherapy in patients with folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer.

CRISPR, the gene editing technique that promises to revolutionize healthcare and medicine, is not perfect. Two new studies, one in mice embryos and the other in rice plants, seem to confirm this.

Until recently, they were considered to be the three pillars of cancer treatment. Recent years have added a fourth pillar to surgery, radiation and chemotherapy—immuno-oncology.

Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections has entered into an agreement to divest Xellia’s Raleigh, North Carolina manufacturing plant to Sagent Pharmaceuticals Inc., (‘Sagent’), a leader of specialty pharmaceutical products with an emphasis on the injectable market.

Kahn Swick & Foti, LLC and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 25, 2019 to file lead plaintiff applications in a securities class action lawsuit against Diplomat Pharmacy, Inc., if they purchased the Company’s securities between February 26, 2018 and February 21, 2019, inclusive (the “Class Period”).

Hansa Biopharma AB, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced that the European Medicines Agency has accepted the Company’s Marketing Authorization Application for review of IDEFIRIX™.